RxSight Stock (NASDAQ:RXST)
Previous Close
$38.19
52W Range
$33.03 - $66.54
50D Avg
$46.15
200D Avg
$51.60
Market Cap
$1.36B
Avg Vol (3M)
$580.37K
Beta
1.19
Div Yield
-
RXST Company Profile
RxSight, Inc., a medical technology company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery. The company's RxSight system includes RxSight light delivery device, an office-based light treatment device that delivers UV light in a programmed pattern to modify the LAL based on the visual correction needed to achieve desired vision after cataract surgery. It primarily serves cataract doctors. The company was formerly known as Calhoun Vision, Inc. and changed its name to RxSight, Inc. in February 2017. RxSight, Inc. was incorporated in 1997 and is headquartered in Aliso Viejo, California.
RXST Performance
Peer Comparison
Ticker | Company |
---|---|
FNA | Paragon 28, Inc. |
APYX | Apyx Medical Corporation |
OFIX | Orthofix Medical Inc. |
LUNG | Pulmonx Corporation |
NPCE | NeuroPace, Inc. |
KIDS | OrthoPediatrics Corp. |
IRMD | IRadimed Corporation |
SGHT | Sight Sciences, Inc. |
SSKN | STRATA Skin Sciences, Inc. |
VREX | Varex Imaging Corporation |
AXGN | AxoGen, Inc. |
SIBN | SI-BONE, Inc. |
CVRX | CVRx, Inc. |